31 research outputs found
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).
[This corrects the article DOI: 10.1186/s13601-016-0116-9.]
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).
[This corrects the article DOI: 10.1186/s13601-016-0116-9.]
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
Abstract Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing
RESULTS OF THE AUTOLOGOUS MESENCHYMAL STEM CELL TRANSPLANTATION IN PATIENTS WITH TYPE 1DIABETES MELLITUS
Introduction: Type 1diabetes mellitus (T1DM) remains one of the main public healthcare problems
worldwide with a tendency to steady growth. T1DM leads to kidney failure, blindness, heart attacks and
strokes, which account for high rates of morbidity and mortality among patients with T1DM. A replacement
of beta cells is the goal of therapy for T1DM. Recent clinical studies have shown a promising stem
cell role in the treatment of T1DM. We evaluated the therapeutic effect of autologous mesenchymal stem
cell transplantation (AMSCT) on carbohydrate metabolism markers in T1DM patients.
Methods: We examined 7 patients (5 male, 2female, aged 20-42) with T1DM, who underwent AMSCT
(cells were obtained from the patients’ iliac crest and cultivated for 3-4 weeks) by intravenous infusion.
The quantity of autologous mesenchymal stem cells infused was from 95 to 97 × 106. We analyzed the
daily insulin dosages, glycated hemoglobin (HbA1c), glutamic acid decarboxylase (GAD) antibody and
Langerhans antibody levels in patients before, 1, 2and 3 months after the AMSCT procedure.
Results: In patients with T1DM, AMSCT led to decrease in daily insulin dosage levels from 58,81±
13,71Units to 47,5± 12,7 Units (p=0,04) with trend to increase leptin levels and decrease HbA1c levels,
from 7,73 + 3.5 ng/ml to 16,9 ± 8,31ng/ml (p= 0,046) and 9,59±1,73% to 8,65±0,93 % (p = 0,092) after
1month, respectively. GAD antibody and Langerhans antibody levels didn’t change significantly after AMSCT:
from 10,79 + 4,52IU/ml to 12,33 ± 3,81IU/ml (p> 0,05) and 14,12+4,26 IU/mL to 18,17+9,03 IU/mL
(р=0,485) after 3 months, respectively.
Conclusions: The AMSCT led to decrease of the daily insulin dosage levels with increase of the leptin
levels after 1month without increasing of the GAD and Langerhans antibody levels within 3 months in
patients with T1DM
Integrated care pathways for airway diseases (AIRWAYS-ICPs).
The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYSICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers)
Integrated care pathways for airway diseases (AIRWAYS-ICPs).
The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYSICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers)
The Global Alliance against Respiratory Diseases (GARD) Country Report
Prevention, Population and Disease management (PrePoD